Why Cybin Inc.’s (HELP) Stock Is Up 6.67%
As of Monday, September 21, Cybin Inc.’s HELP share price has surged by 6.67%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Commentary & Analysis
Why Cybin Inc.’s (HELP) Stock Is Up 8.89%
As of Monday, September 21, Cybin Inc.’s HELP share price has surged by 8.89%, which has investors questioning if this is right time to sell.Michael Rose
Why Cybin Inc.’s (HELP) Stock Is Up 10.51%
As of Monday, September 21, Cybin Inc.’s HELP share price has surged by 10.51%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Cybin Inc.’s (HELP) Stock Is Up 11.80%
As of Monday, September 21, Cybin Inc.’s HELP share price has surged by 11.80%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Cybin Inc.’s (HELP) Stock Is Up 12.21%
As of Monday, September 21, Cybin Inc.’s HELP share price has surged by 12.21%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | HELP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $927.9 | $541.1 | 45% |
|
| Shares Out (Mil) | 52.3 | 42.5 | 49% |
|
| Institutional Ownership | 72.7% | 84.5% | 44% |
|
| Float (Mil) | 58.6 | 45.7 | 50% |
|
| Beta | 0.63 | 0.72 | 37% |
|
| Avg Daily Volume (000s) | 2,131 | 417 | 81% |
|
| Price Change (52-week) |
116.7% | 61.9% | 95% |
|
| Growth | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (42.0%) | (1.4%) | 9% |
|
| EPS (5yr) | 15.3% | 15.1% | 58 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (40.2%) | (15.0%) | 11% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 2 | |
| Current EPS | ($0.668) | ($2.620) | ($1.789) | |
| Month Ago EPS | ($0.665) | ($2.610) | ($1.789) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.755) | ($3.007) | ($2.890) | |
| Year/Year Chg | (26.9%) | (38.4%) | (78.7%) | |
| Financials | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($171) | ($11) | 8% |
|
| EPS (TTM) | ($4.049) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($141) | ($7) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $5 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $739 | $493 | 38% |
|
| Valuation | HELP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.25 | 2.37 | 69% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HELP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.0% | na |
|
| ROA | (72.8%) | (22.2%) | 8% |
|
| ROE | (86.9%) | (22.8%) | 10% |
|
| Liabilities to Assets | 6.8% | 32.8% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Cybin Inc. did not pass any screens on 9/29/2026.
